drugset / Trial / NCT05119907
Study of Sacituzumab Govitecan in Patients With Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to see how effective the study drug, sacituzumab govitecan-hziy, is in participants with solid tumor.
Timeline
- Start
- 2021-10-12
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | Intravenous |